British Medical Bulletin 2001: Vol 58 Index

5 Pages·2001·0.82 MB·English

Index
Acute HIV-1 infection and HIV-1 Central Asia, trends in the HIV pandemic, 15
transmission, 109-127 China and STI/HIV, 130
Adler MW see Weiss RA Chronic asymptomatic HIV-1 infection,
AIDS and the private sector, 83-85 65-69
Anti-retroviral therapy (ART) (see also Circumcision, protective effect of male, 9
HAART), 172, 182-184, 190, 193-200, Clade-specific vaccine design, 209
208 Clapham PR, McKnight A: HIV-i receptors
Antibody responses to vaccines, 212 and cell tropism, 43-59
Antimicrobial resistance (global) of N. Co-receptor use in vivo, variation, 49-50
gonorrhoeae and Haemophilus ducreyi, 145 Co-trimoxazole, 181
Antiretroviral therapies (ART), 7,8, 9, 16 Comprehensive care policy, planning and
Asia (South and South East), demography, implementing, 178-182
7378
Computer-assisted self-interview (CASI),
Australasia, trends in the HIV pandemic, 164
15-16 Condom protected sex, 141-143, 155
Bacterial vaginosis (BV), 147-149 Core groups, 10
Bahamas, demography, 73-88 Cryptosporidium as Ol, 193
Behavioural interventions to prevent HIV CXCR co-receptors, 43, 44-49, 53, 54, 61,
infection: rapid evolution, increasing rigour, 69-70, 111
moderate success: Bonell C, Imrie J, Cytomegalovirus (CMV), 193
155-170 Cytotoxic T-lymphocytes (CTLs), 62-71,
Blood transfusion and transmission, 9 91-92, 94. 96-97, 119, 190-192
Bonell C, Imrie J: Behavioural interventions to epitopes, 21, 30-36, 209
prevent HIV infection: rapid evolution, prevention of HIV infection, 213
increasing rigour, moderate success, responses, 213
155-170
Botswana, demography, 73-88 DC-SIGN on dendritic cells, 43, 48, 52, 63,
Breast-feeding, 99-100 114-115
Burchett S see Goulder PJR Democratic Republic of the Congo (DRC),
evolution of the M group virus in the , 2 4>
Candidate HIV vaccines in clinical trials, Demography and economics of HIV/AIDS:
215-216 Whiteside A, 73-88
Carribean, trends in the HIV pandemic, 15 Dependency ratio and orphaning, 80
Case finding for STIs, 138-139 Detours V see Korber B
CCR for HIV entry into cells, 44-46
CD4- T-lyphocytes, 188-189 East Asia and the Pacific, trends in the HIV
CD8- pandemic, 14
antiviral factor (CAF), 192 Eastern Europe,
anti-HIV suppressor activity (CASA), 192 drug addicts, demography, 73-88
cytotoxic T-lymphocytes, 191-192 trends in the HIV pandemic, 15
effector cells, 190-192 Economics and demography of HIV/AIDS,
suppressor cells, 192 73-88
T-cell re-infusion, 198-199 Epidemiology of
Cell surface receptors (CCR), 43-59, 61-63, HIV/AIDS, global, 7-18
69-70 HIV/AIDS disease burden, 175-178
Cell tropism and HIV STIs, 130-131
in immune and non-immune tissues, 47-49 Evolution of the M group virus in the Demo-
HIV-1 receptors , 43-59 cratic Republic of the Congo (DRC), 23
British Medical Bulletin 2001;58: 219-223 © The British Council 2001
The changing face of HIV and AIDS
RAE ARE EE DTO E TE IETS IPE SE EE ED EE ERD SST EEE ELLE DLE ELL TST TB SE ET SL EEE ST RESELL PES
Evolutionary and immunological effect on Ols, 196-197
implications of contemporary HIV-1 Highly exposed persistently seronegatives
variation: Korber B, Gaschen B, Yusim K, (HEPS), 113-114
Thakallapally R, Kesmir C, Detours V, History, modelling the, of the HIV epidemic
19-42 through phylogenetics, 22-3
HIV (candidate) vaccines in clinical trials,
Factors influencing susceptibility and 215-216
resistance to HIV-1 infection, 112-114 HIV and influenza compared, 29-30
Family planning (FP) clinics and STIs, 136, HIV care in non-industrialised countries:
144 Gilks CF, 171-186
Fertility, 79 HIV clades, importance of, 208-209
Follicular dendritic cell (FDC) network, 119 HIV in adult infection, successful control of,
9 1-92
Gaschen B see Korber B HIV infection
Genetic factors, 112-113 behavioural interventions to prevent,
Genital infection increases HIV-1 155-170
transmission, 111 interventions against sexually transmitted
Genital ulcer disease (GUD) infections (STI) to prevent, 129-153
and HIV, 132 paediatric, 89-108
attributable to HSV-2 infection, 146 HIV seroconversion studies, 133
Gilks CF: HIV care in non-industrialised HIV variation in different tissues,
countries, 171-186 HIV-1 infection
Global epidemiology HIV/AIDS: Morison L, genetic subtypes, 23-5
7-18 factors influencing susceptibility and
GM-CSF therapy, 198 resistance to, 112-114
Gonococeal antimicrobial susceptibility pathogenesis of , 61-72
programme (GASP), 146 HIV-1 receptors and cell tropism: Clapham
Gotch F see Wilkinson J PR, McKnight A, 43-59
Goulder PJR, Jeena P, Tudor-Williams G, HIV-1 transmission and acute HIV-1
Burchett $: Paediatric HIV infection: infection: Hansasuta P, Rowland-Jones SL,
correlates of protective immunity and 109-127
global perspectives in prevention and HIV-1 variants tropic for specialized cells in
management, 89-108 different tissues, 50-51
gp 120 interactions with co-receptors, HIV-1 variation: evolutionary and
46-47, 62-64, 69-70 immunological implications of
gp41 transmembrane, 44 contemporary, 19-42
Gram-negative sepsis, 180-181 HIV-infected immune system, 187-188
Guyana, demography, 73-88 HIV-STI interactions, 131-133
HSV seropositive and HIV seroconversion,
Haiti, demography, 73-88 33
Hanke T: Prospect of a prophylactic vaccine HSV-related Bells palsy, 179
for HIV, 205-218 Human herpes virus 8 (HHV8) as Ol, 193
Hansasuta P, Rowland-Jones SL: HIV-1 Human papilloma virus (HPV) as OI, 193
transmission and acute HIV-1 infection, IL-2 therapy, 198
109-127
Health promotion theory, 157-158 Immune interventions: Wilkinson J, Gotch F
Herpes simplex virus (HSV), 132-133, Immune-based therapies, 197-200
145-147, 149 Immunological
Hierarchy of care, 182-184 and evolutionary implications of
Highly active anti-retroviral contemporary HIV-1 variation, 19-42
therapy/treatment (HAART), 15-16, 52, mechanisms of HIV resistance, 113-114
90, 91,92, 98-101, 172, 182-184, 190, responses to a rapidly evolving pathogen,
193-200, 208 30-7
SPS EE EP SE TS TT SS PEA EI I II EE EE EE TE EE ETE
British Medical Bulletin 2001;58
Immunosuppression and opportunistic Maternal and child health (MCH) clinics
infections, 192-193 and STIs, 136,139,144
Implementing effective behavioural Mayaud P, McCormick D: Interventions
interventions in HIV prevention practice, against sexually transmitted infections
164-165 (STI) to prevent HIV infection, 129-153
Imrie | see Bonell C McCormick D see Mayaud P
India, trends in the HIV pandemic, 13-14 McKnight A see Clapham PR
Infectivity - what influences it? 111 Mechanisms of progression to disease at
Influenza and HIV compared, 29-30 different rates, 92-95
Influenza vaccines: responding to change, Memory cells, 190, 195, 200
28-30 MHC molecules, 189
Information, education and communication Microsporidium as Ol, 193
(IEC) campaigns, 143 Middle-East, trends in the HIV pandemic,
Injecting drug use (IDU), 9, 14 13
Integration of STI prevention and care in MIP chemokines, 113
reproductive health services, 144-145 Modelling the history of the HIV epidemic
Interventions against sexually transmitted through phylogenetics, 22-3
infections (STI) to prevent HIV infection: Models of AIDS, non-primate, 209-210
Mayaud P, McCormick D, 129-153 Morison L: The global epidemiology of
Introduction: Piot P, 3-5 HIV/AIDS, 7-18
Mortality, 75-78
Jeena P see Goulder PJR Mother-to-child transmission (MTCT),
9-10, 16, 77-78, 89-90, 95-104, 112
Kenya, 132, 133 Mwanza, Tanzania, STI control and HIV
breast-feeding in, 100 transmission, 33, 139-140
sex-workers, resistance, 113 Mycobacterium avium complex (MAC), 198
Kesmir C see Korber B
King Edward VIII Hospital (KEH) in Natural history of HIV/AIDS relevant to
Durban, South Africa, paediatric HIV care, 172-175
care 89-108 Newly Independent States (NIS) of the
Korber B, Gaschen B, Yusim K, former Soviet Union, 130
Thakallapally R, Kesmir C, Detours V: Non-industrialised countries: HIV care in,
Evolutionary and immunological 171-186
implications of contemporary HIV-1 Non-primate models of AIDS, 209-210
variation, 19-42 Non-syncytial (NSI slow/low), 69-70
North Africa,
Late stage HIV-1 infection, 69-71 trends in the HIV pandemic, 13
Latin America, trends in the HIV pandemic, North America,
14 trends in the HIV pandemic, 15
Life-expectancy, 78-79
Long-term Opportunistic infections (OIs), 17 5
non-progressors (LTNP), 91-92 and immunosuppression, 192-193
survival, 193
Paediatric HIV care in Durban (SA), London
Macro-economic impacts, 82-83 (UK), and Boston (USA), 89-108
Major histocompatibility complex (MHC). Paediatric HIV infection, correlates of
61 protective immunity and global
Malawi, 132 perspectives in prevention and
paediatric HIV infection, 91, 100 management: Goulder PJR, Jeena P, Tudor-
Male reproductive health services to control Williams G, Burchett $, 89-108
STIs, 145 Paediatric HIV infection,
Mannose-binding lectin (MBL), 113 augmenting, 97-99
Mass treatment of STIs, 139 control of, 95-97
British Medical Bulletin 2001;58
The changing face of HIV and AIDS
pe SE TE EP SS A SES SE LT TIA
management of, 100-104 Sexually transmitted infections (STI),
natural history, 90-91 pA Si ekP P
prevention of, 99-100 control programmes, 133-135
Palliative care, 171, and HIV interactions, 131-133
Partner notification (PN), 136-137 interventions against, to prevent HIV
Pathogenesis of HIV-1 infection: Weber J, infection, 129-153, 135-144
61-72 presumptive treatment, targeted
Peripheral blood mononuclear cells (PBMC), periodic, 140-141
69, 191 prevention, female-controlled, 142-143
Phylogenetics, modelling the history of the Simian immunodeficiency virus (STV)
HIV epidemic through , 22-3 monkey model of HIV, 21, 114-115, 119
Piot P: Introduction, 3-5 model of acute infection, 190-192
Pneumonia, 180-181 Social psychological theories, 158
Population size and growth, 79-80 Sociological theories, 158-160
Pre-packages therapy (PPT) kits, 138 South Africa, 73-88, 100
Preface: Weiss RA, Adler MW & Rowland- South and South-East Asia, trends in the
Jones SL, 1-2 HIV pandemic, 13-14
Prevention of HIV infection and CTL, 213 Structured treatment interruptions, 196
Prevention of HIV infection by behavioural Sub-Sahara Africa,
interventions, 155-170 demography, 73-88, 89
Prevention stategy for HIV infection by paediatric HIV infection, 91, 93
interventions against sexually transmitted trends in the HIV pandemic, 11-12
infections (STI), 129-153 Subunit vaccine challenge experiments in
Primary HIV infection (PHI), non-human primates, 214-215
62-65, 190, 194 Supervised treatment interruption, 98
clinical presentation of , 114-117 Susceptibility and resistance to HIV-1
early events in, 114-116 infection, 112-114
immunopathological events in, 118-120 Swaziland, demography, 73-88
treatment of, 120 Syncytial (SI fast/high), 69-70
Primary prevention of STIs, 141-143 Syndromic management of STI-associated ill-
Primate lentiviruses, 21-2 health, 135-136
Prophylactic vaccine for HIV, prospect of,
205-218 Tanzania, demography, 73-88
Prophylaxis for TB, 181 Thai epidemic, 111
Prospect of a prophylactic vaccine for HIV: Thakallapally R see Korber B
Hanke T, 205-218 Therapeutic vaccines, 199-200
Public health importance of sexually Therapeutic vaccines, 216
transmitted infections, 130-133 Therapies
immune-based, 197-200
Rakai, Uganda and STI control, 139-140 targeted at HIV receptors, 52-54
RANTES Transmission of HIV, 8-11
production, 113 Transmission of HIV-1 and acute HIV-1
recombinant form of, 53 infection: routes and mechanism, 109-127
Resistance and susceptibility to HIV-1 Transmission, mother-to-child (MTCT),
infection, 112-114 77-78, 89-90, 95-104, 112
Rowland-Jones SL see Trends (global) in the HIV pandemic, 11-16
Hansasuta P and Weiss RA Tuberculosis
Russia, demography, 73-88 and HIV, 172, 173, 175, 178, 180-181
as AIDS-related illness, 12
Screening for STIs, 138-139 Tudor-Williams G see Goulder PJR
Self-medication, 137
Sex workers, HIV-seropositive female in Uganda, demography, 73-88
Ivory Coast, 132
British Medical Bulletin 2001;58
Vaccines for HIV, 114 WeberJ : Pathogenesis of HIV-1 infection
paediatric HIV infection, 97-99 61-72
prospect of a prophylactic, 205-218 Weiss RA, Adler MW, Rowland-Jones SL:
Vaccines Preface, 1-2
live-attenuated , 210 Western Europe, trends in the HIV
and long-term survival, 193 pandemic, 15
for STIs, 143 Whiteside A: Demography and economics of
subunit, 210-212 HIV/AIDS, 73-88
therapeutic, 199-200 WHO staging system, 173
whole killed, 210 Wilkinson J, Gotch F: Immune interventions,
Vaginal microbicides, 142 187-203
Vitamin A deficency, increased HIV-1
transmission, 111 Yusim K see Korber B
Voluntary counselling and testing (VCT),
171, 176, 180 Zimbabwe, demography, 73-88
Zulu, South Africa, 93, 100
| aS RS PS ST SE
British Medical Bulletin 2001;58